Cargando…

Management and Treatment Outcomes of High-Risk Corneal Transplantations

Corneal transplantation is the most effective treatment for corneal blindness. Standard planned keratoplasties have a high success rate. Conditions such as active inflammation at the time of surgery, the presence of ocular surface disease, previous graft disease, or neovascularization make them more...

Descripción completa

Detalles Bibliográficos
Autores principales: Urbańska, Karolina, Woźniak, Marcin, Więsyk, Piotr, Konarska, Natalia, Bartos, Weronika, Biszewski, Mateusz, Bielak, Michał, Chorągiewicz, Tomasz, Rejdak, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572799/
https://www.ncbi.nlm.nih.gov/pubmed/36233379
http://dx.doi.org/10.3390/jcm11195511
_version_ 1784810706860769280
author Urbańska, Karolina
Woźniak, Marcin
Więsyk, Piotr
Konarska, Natalia
Bartos, Weronika
Biszewski, Mateusz
Bielak, Michał
Chorągiewicz, Tomasz
Rejdak, Robert
author_facet Urbańska, Karolina
Woźniak, Marcin
Więsyk, Piotr
Konarska, Natalia
Bartos, Weronika
Biszewski, Mateusz
Bielak, Michał
Chorągiewicz, Tomasz
Rejdak, Robert
author_sort Urbańska, Karolina
collection PubMed
description Corneal transplantation is the most effective treatment for corneal blindness. Standard planned keratoplasties have a high success rate. Conditions such as active inflammation at the time of surgery, the presence of ocular surface disease, previous graft disease, or neovascularization make them more susceptible to rejection. These are so-called high-risk corneal transplantations. In our study, we selected 52 patients with a higher risk of graft rejection. A total of 78 procedures were performed. The main indications for the first keratoplasty were infections (59.6%) and traumas (21.2%). Visual acuity (VA) significantly improved from 2.05 logMAR on the day of keratoplasty to 1.66 logMAR in the latest examination (p = 0.003). An analysis of the graft survival showed a 1-year survival of 54% and a 5-year survival of 19.8% of grafts. The mean observation time without complications after the first, second, and third surgery was 23, 13, and 14 months, respectively. The best results were noted among patients with infectious indications for keratoplasty (p = 0.001). Among them, those with bacterial infection had the best visual outcomes (p = 0.047).
format Online
Article
Text
id pubmed-9572799
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95727992022-10-17 Management and Treatment Outcomes of High-Risk Corneal Transplantations Urbańska, Karolina Woźniak, Marcin Więsyk, Piotr Konarska, Natalia Bartos, Weronika Biszewski, Mateusz Bielak, Michał Chorągiewicz, Tomasz Rejdak, Robert J Clin Med Article Corneal transplantation is the most effective treatment for corneal blindness. Standard planned keratoplasties have a high success rate. Conditions such as active inflammation at the time of surgery, the presence of ocular surface disease, previous graft disease, or neovascularization make them more susceptible to rejection. These are so-called high-risk corneal transplantations. In our study, we selected 52 patients with a higher risk of graft rejection. A total of 78 procedures were performed. The main indications for the first keratoplasty were infections (59.6%) and traumas (21.2%). Visual acuity (VA) significantly improved from 2.05 logMAR on the day of keratoplasty to 1.66 logMAR in the latest examination (p = 0.003). An analysis of the graft survival showed a 1-year survival of 54% and a 5-year survival of 19.8% of grafts. The mean observation time without complications after the first, second, and third surgery was 23, 13, and 14 months, respectively. The best results were noted among patients with infectious indications for keratoplasty (p = 0.001). Among them, those with bacterial infection had the best visual outcomes (p = 0.047). MDPI 2022-09-20 /pmc/articles/PMC9572799/ /pubmed/36233379 http://dx.doi.org/10.3390/jcm11195511 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Urbańska, Karolina
Woźniak, Marcin
Więsyk, Piotr
Konarska, Natalia
Bartos, Weronika
Biszewski, Mateusz
Bielak, Michał
Chorągiewicz, Tomasz
Rejdak, Robert
Management and Treatment Outcomes of High-Risk Corneal Transplantations
title Management and Treatment Outcomes of High-Risk Corneal Transplantations
title_full Management and Treatment Outcomes of High-Risk Corneal Transplantations
title_fullStr Management and Treatment Outcomes of High-Risk Corneal Transplantations
title_full_unstemmed Management and Treatment Outcomes of High-Risk Corneal Transplantations
title_short Management and Treatment Outcomes of High-Risk Corneal Transplantations
title_sort management and treatment outcomes of high-risk corneal transplantations
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572799/
https://www.ncbi.nlm.nih.gov/pubmed/36233379
http://dx.doi.org/10.3390/jcm11195511
work_keys_str_mv AT urbanskakarolina managementandtreatmentoutcomesofhighriskcornealtransplantations
AT wozniakmarcin managementandtreatmentoutcomesofhighriskcornealtransplantations
AT wiesykpiotr managementandtreatmentoutcomesofhighriskcornealtransplantations
AT konarskanatalia managementandtreatmentoutcomesofhighriskcornealtransplantations
AT bartosweronika managementandtreatmentoutcomesofhighriskcornealtransplantations
AT biszewskimateusz managementandtreatmentoutcomesofhighriskcornealtransplantations
AT bielakmichał managementandtreatmentoutcomesofhighriskcornealtransplantations
AT choragiewicztomasz managementandtreatmentoutcomesofhighriskcornealtransplantations
AT rejdakrobert managementandtreatmentoutcomesofhighriskcornealtransplantations